Sarah Cavanaugh - Jun 5, 2025 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP OF CORP AFFAIRS & ADMIN.
Signature
/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh
Stock symbol
CLDX
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
4
Date filed
6/9/2025, 04:22 PM
Previous filing
Jun 17, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON /s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh 2025-06-09 0001709113

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (right to buy) Award $0 +78K $0.00 78K Jun 5, 2025 Common Stock 78K $19.53 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.